Panacea Biotec Limited
Massachusetts Institute Of Technology increased its stake in Panacea Biotec from 1.12% to 1.71%, raising its shareholding from 6,85,000 to 10,50,000 shares. The value of the additional 3,65,000 shares is ₹16.86 Cr at ₹461.95 apiece.
A research-based biotechnology company, Panacea Biotec develops and manufactures pharmaceutical products and vaccines across multiple therapeutic areas including immunology, oncology, and infectious diseases. Incorporated in 1984, the company operates through integrated manufacturing facilities and maintains a strong focus on developing affordable healthcare solutions for emerging markets. Its distinctive strength lies in combining advanced biotechnology research capabilities with specialized vaccine production expertise and a commitment to accessible medicine.
Listed equity holdings of MIT's endowment, managed by MIT Investment Management Company (MITIMCo). Endowment manages over USD 23 billion.